Get the Stockscreener App
2.00
5.59%
-0.13
Gain Therapeutics Inc stock is traded at $2.00, with a volume of 38,328.
It is down -5.59% in the last 24 hours and down -6.90% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$2.13
Open:
$2.12
24h Volume:
38,328
Relative Volume:
0.17
Market Cap:
$54.11M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.8182
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-3.32%
1M Performance:
-6.90%
6M Performance:
+93.37%
1Y Performance:
-57.03%
1-Day Range:
$1.98
$2.13
1-Week Range:
$1.84
$2.1452
52-Week Range:
$0.89
$5.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.005 | 54.11M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.18 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.05 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
636.58 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
113.23 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Finance
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales - MSN
GAIN THERAPEUTICS: A Microcap Stock to Love - substack.com
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Investing in Neurizon Therapeutics (ASX:NUZ) five years ago would have delivered you a 54% gain - Yahoo Finance
Does Gain Therapeutics Inc (NASDAQ: GANX) Still Need To Convince Analysts? - Stocks Register
2025 Pipeline Report: The Edge of Greatness? - Pharmaceutical Executive
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Travere Therapeutics Delivers Over 180% Gain In 6 Months - Nasdaq
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Benzinga
Verve Therapeutics Inc (VERV)’s stock decline to 7.98 per share - US Post News
Novartis to Buy Anthos Therapeutics for $925 Million - Bloomberg
Daily Progress: Wearable Devices Ltd (WLDS) Gain 1.76, Closing at 0.95 - The Dwinnex
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research - The Globe and Mail
Janux Therapeutics Inc (NASDAQ: JANX) Gain Of 80.16% Compared To 52-Week Low; YTD Fall -26.47% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
reAlpha Tech Corp (NASDAQ: AIRE) Gain Of 70.56% Compared To 52-Week Low; YTD Fall -37.72% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Sacks Parente Golf Inc (NASDAQ: SPGC): Can The Stock Still Lose Despite An 38.15% YTD Gain? - Marketing Sentinel
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials - TipRanks
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - citybiz
Travere Therapeutics Inc (TVTX) deserves deeper analysis - US Post News
Can you now get a good deal on PTC Therapeutics Inc’s shares? - US Post News
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Philip Morris Q4: Earnings Beat, Smoke-Free Sales Gain Ground & More - Yahoo Finance
Gain Therapeutics, Inc. Provides 2025 Outlook and Progress Update on GT-02287 for Parkinson’s Disease - Nasdaq
Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching - StockTitan
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – What’s Next? - Defense World
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval - Yahoo Finance
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Gain Therapeutics To Participate in Upcoming Investor Conferences - The Manila Times
Gain Therapeutics, Inc. Announces Upcoming Presentations at BIO CEO & Investor Conference and Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
Biotech Spotlight: Gain Therapeutics Takes Center Stage at Two Major Investor Conferences - StockTitan
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Closing Figures Unveiled: Canada Goose Holdings Inc (GOOS) Gain 1.05, Closes at 10.57 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
Gene editing companies to gain from FDA’s platform designation update - BioCentury
How to interpret Omega Therapeutics Inc (OMGA)’s stock chart patterns - US Post News
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Closing Figures Unveiled: Ondas Holdings Inc (ONDS) Gain 3.55, Closes at 1.75 - The Dwinnex
2025's 10 Best-Performing Stocks - U.S News & World Report Money
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gain Therapeutics Inc Stock (GANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
| Riley Jeffrey Scott | Director |
Mar 28 '24 |
Buy |
3.86 |
30,000 |
115,770 |
30,000 |
2.93%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):